tirzepatide/niacinamide 17/2 mg/ml Tirzepatide is the dual-action one. Instead of working on a single hormone, it targets two — GLP-1 and GIP — which is why it tends to have a stronger effect on appetite How GLP-1s affect type 2

I use it from time to time to expedite healing, especially in people with IBS or small intestinal bacterial overgrowth (SIBO)

Sprem M et al

Summary Microdosing is typically treated as a tolerability-first, clinician-guided approach, involving starts below the usual 2.5 mg step, extending escalation windows from 4 to 8 weeks or more, or pausing at intermediate maintenance doses, such as 5 mg or 7.5 mg, to prioritize steady adherence and symptom control

Unfortunately, most regain two-thirds of their lost weight within a year as well as worsening of metabolic health indicators (Mozaffarian et al., 2025

Assessment of factors influencing glymphatic activity and implications for clinical medicine